DeBeurs.nl

aossa 27 september 2009 15:35

0

Report on the global biosimilars market
25. september 2009 07:15

Reportlinker Adds Biosimilars (2009 - 2014)

www.reportlinker.com/p0150471/Reportl...

Report Description

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others.

The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilarss market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Asia’s early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddy’s Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

Scope of the Report

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

• Biosimilars product market

Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

• Biosimilars service market

Contract research and manufacturing services, clinical trials services

• Biosimilars applications market

Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases

• Biosimilars technology market

Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

What makes our reports unique?

• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.

• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW (Rest of the World).

• We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

• 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

• Comprehensive market analysis for the following sectors: Pharmaceuticals, medical devices, biotechnology, semiconductor and electronics, energy and power supplies, food and beverages, chemicals, advanced materials, industrial automation, and telecom and it. we also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?

• What are market estimates and forecasts; which markets are doing well and which are not?

• Where are the gaps and opportunities; what is driving the market?

• Which are the key playing fields? Which are the winning edge imperatives?

• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

aossa 27 september 2009 15:36

0

Research and Markets: Opportunities For Biosimilars Market Is Immense, As Biologics Worth US$25 Billion Are Going To Be Off-Patent By 2016

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/85cb7f/biosimilars_2009) has announced the addition of the "Biosimilars (2009 - 2014)" report to their offering.

The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others.

The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drug during development stages. However, opportunities for biosimilars market is immense, as biologics worth US$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Asia's early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

Scope of the Report:

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

Biosimilars product market Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

Biosimilars service market Contract research and manufacturing services, clinical trials services

Biosimilars applications market Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases

Biosimilars technology market Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

What makes our reports unique?

* We provide the longest market segmentation chain in this industry- not many reports provide market breakdown up to level 5.
* Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and a minimum of 50 micro markets, which are collectively exhaustive and mutually exclusive.
* No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies - US, Europe, APAC, ROW (Rest of the World).
* We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
* 15 pages of high level analysis including benchmarking strategies, best practices and the market's cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
* Comprehensive market analysis for the following sectors: Pharmaceuticals, medical devices, biotechnology, semiconductor and electronics, energy and power supplies, food and beverages, chemicals, advanced materials, industrial automation, and telecom and it. we also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered:

* Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
* What are market estimates and forecasts; which markets are doing well and which are not?
* Where are the gaps and opportunities; what is driving the market?
* Which are the key playing fields? Which are the winning edge imperatives?
* How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Key Topics Covered:

* INTRODUCTION
* SUMMARY
* MARKET OVERVIEW
* BIOSIMILAR PRODUCTS
* BIOSIMILAR SERVICE MARKET
* BIOSIMILAR APPLICATION MARKET
* BIOSIMILAR TECHNOLOGY
* GEOGRAPHIC ANALYSIS
* REGULATORY GUIDELINES
* COMPANY PROFILES
* PATENT ANALYSIS
* APPENDIX
* Patent Expiry In 2008 And Before
* U.S. Biopharmaceutical Patents
* European Biopharmaceutical Patents
* Asian Biopharmaceutical Patents
* Patent Expiry In 2009 And After
* U.S. Biopharmaceutical Patents
* European Biopharmaceutical Patents
* Asian Biopharmaceutical Patents
* LIST OF TABLES
* LIST OF FIGURES
* LIST OF ACRONYMS AND ABBREVIATIONS

Companies Mentioned:

* Anhui Anke Biotechnology (Group) Co., Ltd
* Bharat Biotech
* Bioclones (Pty) Ltd.
* Biopartners
* Cangene
* Cinnagen Inc.
* Claris Lifesciences
* Dong-A Pharmaceutical
* Dr. Reddy'S Laboratories
* Dsm Biologics
* Dynavax Technologies
* Emcure
* Genescience Pharmaceuticals Co Ltd.
* Gtc Biotherapeutics Ltd.
* Hospira Inc.
* Intas Biopharmaceutilcals Ltd.
* Lg Life Sciences
* Maxygen
* Merck
* Momenta
* Phage Biotech Corporation
* Prolong Pharmaceuticals
* Ranbaxy
* Reliance Genemedix Plc 1
* Scinopharm Taiwan, Ltd.
* Shantha Biotech
* Stada Arzneimittel Ag
* Teva Pharmaceutical Industries Ltd.
* Viropro International Inc.
* Wockhardt Limited

For more information visit www.researchandmarkets.com/research/8...

finance.yahoo.com/news/Research-and-M...

voda 28 september 2009 16:31

0

Solvay verkoopt farma-divisie aan Abbott voor EUR5,2 mrd

BRUSSEL (Dow Jones)--Het Belgische chemiebedrijf Solvay SA kondigt maandag aan de farmaceutische activiteiten te verkopen aan de Amerikaanse concurrent Abbott Laboratories voor in totaal EUR5,2 miljard.

De overnameprijs omvat een eerste betaling in contanten van EUR4,5 miljard, bijkomende betalingen tot EUR300 miljoen en de overname van bepaalde verplichtingen van zo'n EUR400 miljoen.

Alle werknemers van de farmaceutische activiteiten van Solvay zullen overgaan naar Abbott. In 2008 haalde Solvay Pharmaceuticals een omzet van EUR2,7 miljard. Bij de farmaceutische divisie werken wereldwijd meer dan 9.000 mensen.

De transactie zal naar verwachting worden afgesloten in het eerste kwartaal van 2010. De impact van de transactie op de resultaten van Solvay zullen bij de afronding bekend worden gemaakt.

Na afronding van de verkoop zal Solvay de inkomsten herinvesteren in organische en aanzienlijke externe groei, met het oog op waardecreatie op lange termijn. Dit zal gebeuren door te investeren in activiteiten met een hoge toegevoegde waarde en in strategische projecten in chemie en kunststoffen. Studies over de herinvesteringen worden al uitgevoerd.

Citigroup, Morgan Stanley en Rothschild waren de financiele adviseurs van Solvay voor deze transactie.

- Door Martijn Mom; Dow Jones Nieuwsdienst; +31-20-5715 201; martijn.mom@dowjones.com

[verwijderd] 7 oktober 2009 12:36

0

Vical's TransVax(TM) CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial

Press Release
Source: Vical Incorporated
On 6:30 am EDT, Wednesday October 7, 2009

SAN DIEGO, Oct. 7, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) announced today that the company's TransVax(TM) cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial. Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, presented the data today at the World Vaccine Congress (Lyon, France - October 5-8).

"T-cell responses are very important in protecting recovering transplant recipients against CMV disease," said Dr. Rolland, "and we were pleased to see that the T-cell responses to both CMV antigens encoded by our vaccine, noted in our four-month interim analysis, were sustained through the seven-month data point. In addition, we saw a promising emerging trend in the antibody response against CMV after the last of four scheduled injections. We look forward to reviewing the final trial data in the first half of 2010."

DRW

aossa 7 oktober 2009 13:02

0

"Some of this investment will be used to build a manufacturing facility for GSK’s paediatric MMR vaccine Priorix. Once the facility is complete it will supply vaccines to the Chinese market."

"The partners are also working to develop and manufacture paediatric vaccines for the Chinese market. GSK is transferring technology to allow the joint venture to manufacture vaccines locally."

voda 8 oktober 2009 18:47

0

Pharming rondt conversie af, verlaagt schuld met EUR25 mln

AMSTERDAM (Dow Jones)--Pharming heeft de conversie van 70% van zijn uitstaande obligaties afgerond waarmee het biotechconcern de converteerbare schuld met bijna EUR25 miljoen heeft verlaagd.

Zoals bekend gaf 70% van de obligatiehouders van Pharming aan in te willen gaan op het bod om hun obligaties om te wisselen in een combinatie van aandelen en contanten. Daarmee werd de ondergrens van 60% die Pharming stelde ruimschoots gehaald.

Pharming bracht in september een bod uit op zijn houders van converteerbare obligaties uit 2007. Het biotechbedrijf bood voor elke obligatie met een nominale waarde van EUR50.000 een bedrag in contanten van EUR7.500 plus 59.000 aandelen.

Als gevolg van de transacties is de grootte van de converteerbare obligaties gereduceerd tot EUR10,9 miljoen van EUR35,8 miljoen. Pharming gaf hiervoor 29,38 miljoen nieuwe aandelen uit en betaalde EUR3,74 miljoen in contanten.

Het benodigde geld werd opgehaald door middel van onderhandse plaatsingen bij bestaande aandeelhouders, waarvoor 3,87 miljoen aandelen worden uitgegeven.

Als gevolg van alle transacties is het aantal uitstaande aandelen van Pharming gegroeid tot 154,5 miljoen.

Bestuursvoorzitter Sijmen de Vries zegt erg tevreden te zijn met de schuldverlaging. Hij spreekt van een significante versterking van de balans, zonder een substantiele hoeveelheid geld te gebruiken. "We blijven werken aan een verdere verbetering van onze financiele positie", vervolgt de CEO.

Obligatiehouders die nog niet hebben gereageerd op het bod van Pharming kunnen dat nog doen tot 13 oktober.

Door Ben Zwirs; Dow Jones Nieuwsdienst; +31-20-5715201; ben.zwirs@dowjones.com

aossa 13 oktober 2009 20:01

0

GenVec schiet uit de krammen!
Volume reeds 11 milj stuks.
Shortsqueeze ?

www.boursorama.com/cours.phtml?symbol...

Rapport (in verschillende stukjes) zie:
messages.finance.yahoo.com/Stocks_%28...

TraderRon 13 oktober 2009 20:32

0

Overnam target / rumors / ordinaire shortsqueeze ?

aossa 13 oktober 2009 20:53

0

quote:
TraderRon schreef:
Overnam target / rumors / ordinaire shortsqueeze ?

Heb jij het rapport gelezen?

TraderRon 13 oktober 2009 21:16

0

Ondertussen wel......

[verwijderd] 14 oktober 2009 13:04

0

Stienstra neemt zowel prive als met beleggingsmaatschappij een belang in Genmab.

www.genmab.com/PressCentre/RecentNews...

aossa 14 oktober 2009 13:49

0

Biotech Short Sellers Changing Beat (AMGN, GILD, BIIB, CELG, GENZ, LIFE, DNDN, HGSI, AMLN, OSIP)
October 12, 2009 · Filed Under Cancer, Financial, General, dendreon, vaccine

Over the weekend we got to see some of the short interest changes for the key biotech stocks. While these was no clear unified directional move, there were some interesting changes seen. Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG), and Genzyme Corp. (NASDAQ: GENZ). Due to growing market caps in the sector, we have also included Life Technologies Corporation (NASDAQ: LIFE), Dendreon Corp. (NASDAQ: DNDN), Human Genome Sciences Inc. (NASDAQ: HGSI), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), and OSI Pharmaceuticals Inc. (NASDAQ: OSIP)in the run down this month.

Amgen Inc. (AMGN)
AS OF DATE Short Int. Change
9/30/2009 18,363,198.. 5% GAIN
9/15/2009 17,449,497

Gilead Sciences Inc. (NASDAQ: GILD)
AS OF DATE Short Int. Change
9/30/2009 16,015,311.. 3.8% GAIN
9/15/2009 15,466,285

Celgene Corporation (NASDAQ: CELG)
AS OF DATE Short Int. Change
9/30/2009 8,177,698.. 9% DROP
9/15/2009 8,935,957

Biogen Idec Inc. (NASDAQ: BIIB)
AS OF DATE Short Int. Change
9/30/2009 9,459,673.. 1% DROP
9/15/2009 9,565,418

Genzyme Corp. (NASDAQ: GENZ)
AS OF DATE Short Int. Change
9/30/2009 8,771,379.. 19% GAIN
9/15/2009 7,388,108

Life Technologies Corporation (NASDAQ: LIFE)
AS OF DATE Short Int. Change
9/30/2009 6,799,196.. 3% DROP
9/15/2009 7,033,841

Dendreon Corp. (NASDAQ: DNDN)
AS OF DATE Short Int. Change
9/30/2009 8,939,869.. 2% DROP
9/15/2009 9,146,253

Human Genome Sciences Inc. (NASDAQ: HGSI)
AS OF DATE Short Int. Change
9/30/2009 19,786,339.. 1% DROP
9/15/2009 19,867,823

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN)
AS OF DATE Short Int. Change
9/30/2009 13,171,869.. 5.7% DROP
9/15/2009 13,928,154

OSI Pharmaceuticals Inc. (NASDAQ: OSIP)
AS OF DATE Short Int. Change
9/30/2009 5,444,450.. 5.8% GAIN
9/15/2009 5,137,212

JON C. OGG

tinyurl.com/ykxpk33

[verwijderd] 14 oktober 2009 13:53

0

GlaxoSmithKline Raised To Buy From Neutral By UBS
Sanofi-Aventis Raised To Neutral From Sell By UBS

Dow Jones Newswire

Dirk

[verwijderd] 14 oktober 2009 20:34

0

Wellicht een interessant bericht: de visie van een sns securities analist op de Nederlandse biotechsector incl enkele koersdoelen voor deze bedrijven. De doelen liggen ruim boven de huidig koersen

www.deaandeelhouder.nl/news/2009/10/1...

[verwijderd] 15 oktober 2009 12:57

0

Oxigene To Acquire Fellow Drug Developer VaxGen In $22M Deal
Last update: 10/15/2009 6:46:56 AM

DOW JONES NEWSWIRES
Biopharmaceutical firm Oxigene Inc. (OXGN) agreed to acquire peer VaxGen Inc. (VXGN) for about $22 million in stock, joining the wave of consolidation in the pharmaceuticals sector.

It is especially acute among drug-development firms, many of which are cash strapped amid lukewarm investor interest in giving some additional capital.

The deal will give Oxigene some $33 million cash currently on VaxGen's books. Thursday's deal calls for holders of VaxGen, which makes boosters for vaccines, to get 0.4719 OxiGene share for every share of VaxGen.

That values the later at 67 cents, a 4.3% discount to Wednesday's closing price. Vaxgen holders would own about 20% of Oxigene at closing - due in the first quarter - and they could build the stake up to 28% if another 8.5 million shares that Oxigene will put into escrow are given to VaxGen holders.

That will take place if certain goals are met. Oxigene doesn't yet have revenue, either, and its lead drug candidate is a thyroid-cancer treatment.

-By Kevin Kingsbury; Dow Jones Newswires; 212-416-2354; kevin.kingsbury@dowjones.com

DRW

flosz 15 oktober 2009 13:13

0

Vaxgen…pfff, dat daar na anthrax etc. nog iets van over is gebleven.
**************

Celltrion History
In the spring of 2002, VaxGen, a California-based biotechnology company, and a group of Korean partners founded what will be the largest biopharmaceutical contract manufacturer in Asia. South Korea was selected for its strategic location, access to a growing pharmaceutical market in the region, established local infrastructure and competitive economics.

Crucell Announces STAR® Research License Agreement with Celltrion, Inc.
Leiden, The Netherlands, 8 April 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with Celltrion, Inc. for the production of recombinant proteins. Under the agreement, Celltrion will evaluate Crucell's STAR® technology for generating cell lines for the manufacture of biopharmaceuticals. Financial details of the agreement were not disclosed.
www.iex.nl/forum/topic.asp?forum=228&...

voda 15 oktober 2009 16:28

0

UBS vergroot belang in Pharming tot 8,30% - Wft

AMSTERDAM (Dow Jones)--UBS AG heeft het belang in Pharming Group nv uitgebreid tot 8,30%. Dit blijkt donderdag uit een melding in het kader van de Wet op het financiele toezicht (Wft).

De meldingsplicht is ontstaan op 8 oktober 2009. Het belang wordt voor 0,05% rechtstreeks reeel gehouden en voor 8,25% rechtstreeks potentieel en bestaat in totaal uit 12.819.760 gewone aandelen. Het stemrecht bedraagt 8,30%.

De vorige melding van UBS in Pharming dateert van 9 juni 2009. Toen bedroeg het belang 4,93%, bestaande uit 4.954.545 gewone aandelen.

Pharming kondigde op 8 oktober 2009 aan de conversie van 70% van zijn uitstaande obligaties afgerond waarmee het biotechconcern de converteerbare schuld met bijna EUR25 miljoen heeft verlaagd.

Pharming bracht in september een bod uit op zijn houders van converteerbare obligaties uit 2007. Het biotechbedrijf bood voor elke obligatie met een nominale waarde van EUR50.000 een bedrag in contanten van EUR7.500 plus 59.000 aandelen.

Het benodigde geld werd opgehaald door middel van onderhandse plaatsingen bij bestaande aandeelhouders, waarvoor 3,87 miljoen aandelen worden uitgegeven. Als gevolg van alle transacties is het aantal uitstaande aandelen van Pharming gegroeid tot 154,5 miljoen.

- Door Martijn Mom; Dow Jones Nieuwsdienst; +31-20-5715 201; martijn.mom@dowjones.com

voda 15 oktober 2009 16:28

0

Roche verhoogt omzetverwachting 2009

ZURICH (Dow Jones)--Roche Holding AG heeft donderdag de omzetverwachting voor 2009 verhoogd na een sterker dan verwachte stijging van de omzet in de eerste negen maanden. Het Zwitserse farmaceutische concern zag de omzet in de eerste negen maanden van 2009 met 9% stijgen tot CHF36,4 miljard (ca. EUR24 mrd), van CHF33,31 miljard een jaar eerder.

De omzetstijging werd gedreven door de portfolio van medicijnen tegen kanker en het griepvaccin Tamiflu. De omzet kwam licht hoger uit dan de CHF36,2 miljard die analisten hadden voorzien.

De omzet van de farmaceutische divisie klom met 12% tot CHF29,03 miljard. De vraag naar Tamiflu bleef volgens Roche sterk in het derde kwartaal. Roche voorziet nu een omzet van het griepvaccin in 2009 van CHF2,7 miljard, tegen een eerdere verwachting van CHF2,0 miljard. Voor 2010 is de omzetverwachting voor Tamiflu opgeschroefd tot CHF700 miljoen, van een eerdere verwachting van CHF400 miljoen.

Voor de gehele farmaceutische divisie voorziet Roche nu ten minste een hoge eencijferige omzetgroei in 2009. De totale omzetgroei zal naar verwachting 'ruim boven' de marktgroei liggen. Eerder ging Roche uit van een omzetgroei van 'net boven' de marktgroei.

De verwachting van een tweecijferige groei van de winst per aandeel in 2009 en 2010 blijft gehandhaafd.

- Door Martijn Mom; Dow Jones Nieuwsdienst; +31-20-5715 201; martijn.mom@dowjones.com

voda 15 oktober 2009 18:09

0

Omega Pharma omzet stijgt 4% in KW3 2009

AMSTERDAM (Dow Jones)--Omega Pharma heeft de omzet in het derde kwartaal van 2009 met 4% zien groeien ten opzichte van een jaar geleden, zo meldt det farmaceutische bedrijf uit Belgie donderdag.

"In het derde kwartaal werd het eerste prille economische herstel waargenomen", licht Omega Pharma toe. In West-Europa nam onmiddellijk de vraag toe, aldus het concern. Daarnaast werd het kostenbesparingsplan verder uitgevoerd.

De omzet van Omega Pharma, specialist in voorschriftvrije geneesmiddelen en gezondheidsproducten, steeg tot EUR189,0 miljoen van EUR182,5 miljoen vorig jaar. Vooral de omzetgroei van 15% in Belgie naar EUR54,0 miljoen viel op.

"De omzetcijfers van het derde trimester tonen aan dat de vraag naar Omega Pharma-producten in West-Europa opnieuw aantrekt. Hierdoor wordt bevestigd dat de omzet 2009, ondanks het zwakkere eerste semester, in de buurt zal liggen van de jaaromzet 2008", aldus het Belgische bedrijf.

Door Ben Zwirs; Dow Jones Nieuwsdienst; +31-20-5715201; ben.zwirs@dowjones.com

aossa 15 oktober 2009 19:33

0

Omega Pharma is geen biotechbedrijf maar OTC verkoper.

AEX 937,58 -1,00 -0,11% 21 feb


Germany40^	22.179,70	-0,60%
BEL 20	4.405,39	+0,82%
Europe50^	5.441,66	-0,61%
US30^	43.424,20	0,00%
Nasd100^	21.616,30	0,00%
US500^	6.014,32	0,00%
Japan225^	38.152,90	0,00%
Gold spot	2.935,70	0,00%
EUR/USD	1,0460	0,00%
WTI	70,19	0,00%

HEIJMANS KON	+13,94%
Brunel	+7,40%
TomTom	+3,22%
JDE PEET'S	+2,84%
BESI	+2,31%

EBUSCO HOLDING	-5,03%
THEON INTERNAT	-2,07%
CM.COM	-1,85%
Arcadis	-1,83%
NN Group	-1,82%

Crucell « Terug naar discussie overzicht

Sectornieuws - Biotech en Pharma

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers